Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854901 | 0.77 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9ACREBBP | |
| SCHEMBL20558246 | 0.75 | KDM4C (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL857006 | 0.74 | ALDH1A1 (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12709547 | 0.70 | P2RX3 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14768555 | 0.70 | USP2 (0.43) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6994576 | 0.70 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12738804 | 0.70 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12489688 | 0.70 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6994573 | 0.70 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL4317051 | 0.69 | ICAM1 (0.45) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113543782-B | Pharmaceutical composition for preventing hair whitening and preventing or treating leukotrichia or vitiligo | 仁荷大学校产学协力团 | 2024-01-16 | — | — | CN | claimed |
| US-20220000832-A1 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo | INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-01-06 | — | — | US | claimed |
| CN-113543782-A | Pharmaceutical composition for preventing hair from whitening and preventing or treating leukotrichia or vitiligo | 仁荷大学校产学协力团 | 2021-10-22 | — | — | CN | claimed |
| WO-2020159146-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING GREYING OF HAIR AND PREVENTING OR TREATING POLIOSISOR VITILIGO | 인하대학교 산학협력단 | 2020-08-06 | — | — | WO | claimed |
| CN-113543782-B | Pharmaceutical composition for preventing hair whitening and preventing or treating leukotrichia or vitiligo | 仁荷大学校产学协力团 | 2024-01-16 | — | — | CN | disclosed |
| US-20220000832-A1 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo | INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-01-06 | — | — | US | disclosed |
| US-20220000832-A1 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo | INHA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-01-06 | — | — | US | disclosed |
| CN-113543782-A | Pharmaceutical composition for preventing hair from whitening and preventing or treating leukotrichia or vitiligo | 仁荷大学校产学协力团 | 2021-10-22 | — | — | CN | disclosed |
| WO-2020159146-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING GREYING OF HAIR AND PREVENTING OR TREATING POLIOSISOR VITILIGO | 인하대학교 산학협력단 | 2020-08-06 | — | — | WO | disclosed |
| WO-2020159146-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING GREYING OF HAIR AND PREVENTING OR TREATING POLIOSISOR VITILIGO | 인하대학교 산학협력단 | 2020-08-06 | — | — | WO | disclosed |
| EP-2440555-B1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8580831-B2 | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010143116-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | MEN1 4630/4885KMT2A 3813/4885KDM4C 4822/4885 |
| US-20220000832-A1 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo | TYR, MC1R, SDHB | MEN1 1172/4885KMT2A 3291/4885KDM4C 3634/4885 |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | AFF1, SULT2A1, NAT1 | MEN1 854/4885KMT2A 187/4885KDM4C 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.